IQVIA HOLDINGS INC
NYSE: IQV (IQVIA Holdings, Inc.)
Last update: 14 hours ago163.85
-5.55 (-3.28%)
| Previous Close | 169.40 |
| Open | 167.58 |
| Volume | 1,526,946 |
| Avg. Volume (3M) | 2,042,408 |
| Market Cap | 27,805,345,792 |
| Price / Earnings (TTM) | 20.90 |
| Price / Earnings (Forward) | 13.14 |
| Price / Sales | 1.77 |
| Price / Book | 4.29 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | 7.88% |
| Operating Margin (TTM) | 13.39% |
| Diluted EPS (TTM) | 6.89 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Quarterly Earnings Growth (YOY) | -26.70% |
| Total Debt/Equity (MRQ) | 272.12% |
| Current Ratio (MRQ) | 0.840 |
| Operating Cash Flow (TTM) | 2.62 B |
| Levered Free Cash Flow (TTM) | 2.45 B |
| Return on Assets (TTM) | 5.16% |
| Return on Equity (TTM) | 19.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | IQVIA Holdings, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 1.05% |
| % Held by Institutions | 98.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Longview Partners (Guernsey) Ltd | 31 Dec 2025 | 2,220,424 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 255.00 (Jefferies, 55.63%) | Buy |
| Median | 221.00 (34.88%) | |
| Low | 200.00 (Citigroup, 22.06%) | Hold |
| Average | 225.44 (37.59%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 181.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 09 Mar 2026 | 213.00 (30.00%) | Buy | 178.55 |
| 22 Jan 2026 | 245.00 (49.53%) | Hold | 239.05 | |
| Barclays | 06 Mar 2026 | 210.00 (28.17%) | Buy | 174.49 |
| 06 Feb 2026 | 210.00 (28.17%) | Hold | 187.49 | |
| RBC Capital | 03 Mar 2026 | 221.00 (34.88%) | Buy | 173.96 |
| Truist Securities | 19 Feb 2026 | 245.00 (49.53%) | Buy | 169.36 |
| 08 Jan 2026 | 290.00 (76.99%) | Buy | 243.19 | |
| Citigroup | 06 Feb 2026 | 200.00 (22.06%) | Hold | 187.49 |
| JP Morgan | 06 Feb 2026 | 225.00 (37.32%) | Buy | 187.49 |
| Jefferies | 06 Feb 2026 | 255.00 (55.63%) | Buy | 187.49 |
| Stifel | 06 Feb 2026 | 220.00 (34.27%) | Buy | 187.49 |
| UBS | 06 Feb 2026 | 240.00 (46.48%) | Buy | 187.49 |
| 08 Jan 2026 | 280.00 (70.89%) | Buy | 243.19 | |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance |
| 29 Jan 2026 | Announcement | IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration |
| 22 Jan 2026 | Announcement | IQVIA Named to the Fortune® World’s Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year |
| 20 Jan 2026 | Announcement | IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |